Applications of magnetoliposomes with encapsulated doxorubicin for integrated chemotherapy and hyperthermia of rat C6 glioma

Babincová, Natália; Sourivong, P.; Babinec, Peter; Bergemann, Christian; Babincová, Melánia; Durdík, Štefan

doi:10.1515/znc-2017-0110

Cited by 41 publications

(35 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,43 Hyperthermia or thermal therapy, ie raising the temperature of tumor tissues to 40-45°C, has provided acceptable benefits and is a promising approach for cancer treatment. [44][45][46] At this temperature range, heat inhibits the regulatory and growth processes of cancerous cells. Heating tumors to above physiological temperatures is not only cytotoxic but also activates several mechanisms by which tumor cells are sensitized to the primary treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>Preparation and Evaluation of Doxorubicin-Loaded PLA–PEG–FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy</p>

Khammarnia¹,

Nourbakhsh²,

Saber³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Among the novel cancer treatment strategies, combination therapy is a cornerstone of cancer therapy. Materials and Methods: Here, combination therapy with targeted polymer, magnetic hyperthermia and chemotherapy was presented as an effective therapeutic technique. The DOX-loaded PLA-PEG-FA magnetic nanoparticles (nanocarrier) were prepared via a double emulsion method. The nanocarriers were characterized by particle size, zeta potential, morphology, saturation magnetizations and heat generation capacity, and the encapsulation efficiency, drug content and in-vitro drug release for various weight ratios of PLA:DOX. Then, cytotoxicity, cellular uptake and apoptosis level of nanocarrier-treated cells for HeLa and CT26 cells were investigated by MTT assay, flow cytometry, and apoptosis detection kit. Results and Conclusions: The synthesized nanoparticles were spherical in shape, had low aggregation and considerable magnetic properties. Meanwhile, the drug content and encapsulation efficiency of nanoparticles can be achieved by varying the weight ratios of PLA:DOX. The saturation magnetizations of nanocarriers in the maximum applied magnetic field were 59/447 emu/g and 28/224 emu/g, respectively. Heat generation capacity of MNPs and nanocarriers were evaluated in the external AC magnetic field by a hyperthermia device. The highest temperature, 44.2°C, was measured in the nanocarriers suspension at w/w ratio 10:1 (polymer:DOX weight ratio) after exposed to the magnetic field for 60 minutes. The encapsulation efficiency improved with increasing polymer concentration, since the highest DOX encapsulation efficiency was related to the nanocarriers' suspension at w/w ratio 50:1 (79.6 ± 6.4%). However, the highest DOX loading efficiency was measured in the nanocarriers' suspension at w/w ratio 10:1 (5.14 ± 0.6%). The uptake efficiency and apoptosis level of nanocarrier-treated cells were higher than those of nanocarriers (folic acid free) and free DOX-treated cells in both cell lines. Therefore, this targeted nanocarrier may offer a promising nanosystem for cancer-combined chemotherapy and hyperthermia.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Preparation and Evaluation of Doxorubicin-Loaded PLA–PEG–FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy</p>

Khammarnia¹,

Nourbakhsh²,

Saber³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Heating to 43 • C enabled controlled release of encapsulated doxorubicin. The results showed inhibition of tumor growth and complete regression [125].…”

Section: Liposomesmentioning

confidence: 95%

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma

et al. 2020

View full text Add to dashboard Cite

Owing to the advancement of technology combined with our deeper knowledge of human nature and diseases, we are able to move towards precision medicine, where patients are treated at the individual level in concordance with their genetic profiles. Lately, the integration of nanoparticles in biotechnology and their applications in medicine has allowed us to diagnose and treat disease better and more precisely. As a model disease, we used a grade IV malignant brain tumor (glioblastoma). Significant improvements in diagnosis were achieved with the application of fluorescent nanoparticles for intraoperative magnetic resonance imaging (MRI), allowing for improved tumor cell visibility and increasing the extent of the surgical resection, leading to better patient response. Fluorescent probes can be engineered to be activated through different molecular pathways, which will open the path to individualized glioblastoma diagnosis, monitoring, and treatment. Nanoparticles are also extensively studied as nanovehicles for targeted delivery and more controlled medication release, and some nanomedicines are already in early phases of clinical trials. Moreover, sampling biological fluids will give new insights into glioblastoma pathogenesis due to the presence of extracellular vesicles, circulating tumor cells, and circulating tumor DNA. As current glioblastoma therapy does not provide good quality of life for patients, other approaches such as immunotherapy are explored. To conclude, we reason that development of personalized therapies based on a patient’s genetic signature combined with pharmacogenomics and immunogenomic information will significantly change the outcome of glioblastoma patients.

show abstract

“…Tapeinos et al [194] Preclinical Human GBM (U87-MG) Lipid-based magnetic nanovectors (LMNVs) Babincova et al [195] Preclinical Human GBM (U87-MG) Etoposide-carrying human serum albumin immobilized magnetic nanoparticles Babincova et al [191] Preclinical Rodent glioma (C6) Thermosensitive magnetoliposomes containing SPIONs and doxorubicin Jia et al 2018 [189] Preclinical Human GBM (U251) RGE-modified, SPION-, and Cur-loaded exosomes (RGE-Exo-SPION/Cur) Lu et al [188] Preclinical Human GBM (U251) Cetuximab (C225)-encapsulated core-shell Fe 3 O 4 @Au magnetic nanoparticles Nguyen et al [173] Preclinical Human GBM (U87-MG) Fluorescently labeled MPIC micelles (G1@Fe 3 O 4 ) Shirvalilou et al [168] Preclinical Rodent glioma (C6) 5-Iodo-2-deoxyuridine (IUdR)-loaded magnetic nanoparticles (NGO/PLGA) Zhou et al, 2018 [187] Preclinical Human GBM (U87-MG) c(RGDyK) peptide PEGylated Fe@Fe 3 O 4 nanoparticles (RGD-PEG-MNPs) Alphand ery et al [175,176] Preclinical Human GBM (U87-MG-Luc) Magnetosomes (CM) Hamdous et al [177] Preclinical Rodent glioma (GL261 þ RG2); Chitosan (M-Chi), polyethyleneimine (M-PEI), and neridronate (M-Neri) coated nanoparticles Le Fevre et al [174] Preclinical Rodent glioma (GL261) Magnetosomes-poly-L-lysine (M-PLL) and iron oxide nanoparticles Ohtake et al [196] Preclinical Human GBM (U87-MG þ U251 þ YKG) Fe(Salen) nanoparticles Zamora-Mora et al [192] Preclinical Human GBM (A-172) Chitosan nanoparticles (CSNPs) Liu et al [169] Preclinical Human GBM (U87-MG) Ferromagnetic IMO nanoflowers (FIMO-NFs) Shevstov et al [185] Preclinical Rodent glioma (C6) Superparamagnetic iron oxide nanoparticles conjugated with heat shock protein (Hsp70-SPIONs) Pala et al [186] Preclinical Human GBM (U87-MG) Dextran-coated, aptamer-bound, aptamer-fluorescein magnetic NPs (NPAF) Yi et al [162] Preclinical Rodent glioma (C6) Magnetic nano-iron Jiang et al [178] Preclinical Human GBM (U251) Silver nanoparticles (AgNPs) Meenach et al [250] Preclinical Human GBM (M059K) Magnetic PEG-based hydrogel nanocomposites Zhao et al [197] Preclinical Human GBM (U251) Solar-planet structured magnetic nanocomposites (Amino silane coated magnetic nanoparticles) Hua et al [198] Preclinical Rodent glioma (C6) Polymer poly[aniline-co-N-(1-one-butyric acid) aniline] (SPAnH) coated iron oxide nanoparticles Liu et al [179] Preclinical Human GBM (U251); Rodent glioma (C6) Silver nanoparticles (Ag...…”

Section: Mhtmentioning

confidence: 99%

Hyperthermia treatment advances for brain tumors

Skandalakis

Rivera

Rizea

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

Hyperthermia therapy (HT) of cancer is a well-known treatment approach. With the advent of new technologies, HT approaches are now important for the treatment of brain tumors. We review current clinical applications of HT in neuro-oncology and ongoing preclinical research aiming to advance HT approaches to clinical practice. Laser interstitial thermal therapy (LITT) is currently the most widely utilized thermal ablation approach in clinical practice mainly for the treatment of recurrent or deepseated tumors in the brain. Magnetic hyperthermia therapy (MHT), which relies on the use of magnetic nanoparticles (MNPs) and alternating magnetic fields (AMFs), is a new quite promising HT treatment approach for brain tumors. Initial MHT clinical studies in combination with fractionated radiation therapy (RT) in patients have been completed in Europe with encouraging results. Another combination treatment with HT that warrants further investigation is immunotherapy. HT approaches for brain tumors will continue to a play an important role in neuro-oncology.

show abstract

Applications of magnetoliposomes with encapsulated doxorubicin for integrated chemotherapy and hyperthermia of rat C6 glioma

Cited by 41 publications

References 19 publications

<p>Preparation and Evaluation of Doxorubicin-Loaded PLA–PEG–FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy</p>

<p>Preparation and Evaluation of Doxorubicin-Loaded PLA–PEG–FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy</p>

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma

Hyperthermia treatment advances for brain tumors

Contact Info

Product

Resources

About